Market Failure in Public Health

A positive externality arises when an activity benefits people who do not pay for or participate directly in it. Vaccination protects the recipient and can also reduce disease transmission to others, so its social benefit exceeds the benefit considered by an individual purchaser.

Why the market underprovides vaccination

Individuals generally base vaccination decisions on private costs and benefits, while part of the gain accrues to the wider community. Consequently, the social marginal benefit of vaccination exceeds its private marginal benefit, and an unassisted market may produce vaccination coverage below the socially desirable level.

• Reduced transmission protects unvaccinated people, including some who cannot receive a vaccine for medical reasons.
• Individuals cannot usually charge others for this protection, so the external benefit is not reflected fully in the market price.
• High user charges and inability to pay can further reduce uptake, weakening community-wide protection.

How public financing corrects the failure

Public financing can internalise the external benefit by lowering the cost faced by recipients and moving uptake closer to the socially efficient level. Financing may support free provision, subsidised doses, procurement, delivery systems and public information rather than requiring government alone to manufacture or administer vaccines.

• A tax-financed subsidy aligns private incentives more closely with the larger benefit received by society.
• Collective procurement can ensure that socially valuable vaccination reaches groups whose demand would otherwise be constrained by income or access.
• Public financing also advances equity because protection from preventable disease should not depend solely on individual purchasing power.

Limits and policy design

The externality justifies intervention, but not necessarily identical financing for every vaccine or population. The appropriate subsidy depends on disease transmissibility, vaccine effectiveness, safety, cost and the distribution of external benefits.

• Financing should be combined with reliable supply chains, surveillance and credible information because a lower price alone may not secure adequate uptake.
• Policy must balance community protection with informed consent and proportionate public-health measures.

How UPSC asks this